Fourth Annual Antibody-Drug Conjugates

Antibody-drug conjugates continue to show encouraging therapeutic effects against both solid tumors and hematological malignancies and the number of deals, mergers, partnerships and new companies entering this space has grown as a result. This year’s fourth annual Antibody-Drug Conjugates, as part of the PEGS Summit, will continue to showcase updates from the clinic, and highlight the design of next-generation ADCs.